Specific sequence determinants of miR-15/107 microRNA gene group targets.

Epigenetic silencing of nucleolar rRNA genes in Alzheimer's disease.

Biomarkers and evolution in Alzheimer disease.

Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.

Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.

[Anonymous].  2011.  Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.. Neurodegenerative disease management. 1(2):141-156.

Alzheimer disease pathology in subjects without dementia in 2 studies of aging: the Nun Study and the Adult Changes in Thought Study.

Alzheimer disease pathology in subjects without dementia in 2 studies of aging: the Nun Study and the Adult Changes in Thought Study.

[Anonymous].  2011.  Alzheimer disease pathology in subjects without dementia in 2 studies of aging: the Nun Study and the Adult Changes in Thought Study.. Journal of neuropathology and experimental neurology. 70(10):832-40.

Frontal cortex neuropathology in dementia pugilistica.

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

[Anonymous].  2012.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.. Acta neuropathologica. 123(1):1-11.

Widespread suppression of huntingtin with convection-enhanced delivery of siRNA.

Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease.

Studying microRNAs in the brain: technical lessons learned from the first ten years.